Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | HTR2C | P28335 | 3/20 | 0.39 |
| ▸ | HTR2B | P41595 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 6/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | CASR | P41180 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3572234 | 0.93 | HTR2A (0.39) | HTR2AHTR2CHTR2BHTTCCR5 | |
| SCHEMBL1096333 | 0.90 | CCR5 (0.36) | HTR2AHTR2CHTR2BHTTCCR5 | |
| SCHEMBL1096334 | 0.89 | HTR2A (0.37) | HTR2AHTR2CHTR2BHTTCCR5 | |
| SCHEMBL1097191 | 0.84 | CCR5 (0.38) | HTR2AHTR2CHTR2BHTTCCR5 | |
| SCHEMBL1097192 | 0.83 | HTR2A (0.37) | HTR2AHTR2CHTR2BHTTCCR5 | |
| SCHEMBL1096601 | 0.81 | CASR (0.42) | HTTCASR | |
| SCHEMBL1097156 | 0.76 | CASR (0.42) | CCR5CASR | |
| SCHEMBL4094906 | 0.75 | CCR5 (0.43) | CCR5CASR | |
| SCHEMBL4100857 | 0.75 | CASR (0.41) | CCR5CASR | |
| SCHEMBL4067653 | 0.73 | SSTR4 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2085383-A1 | PIPERIDINE DERIVATIVES OR SALTS THEREOF | Astellas Pharma Inc. (JP) | 2009-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | CASR, CYP2R1, HCAR1 | HTR2A 896/4885HTR2C 1025/4885HTR2B 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.